K073144

510(k) SUMMARY

Lanx, LLC's Intervertebral Body Fusion Device

Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared

Lanx, LLC
390 Interlocken Crescent, Suite 890
Broomfield, CO 80021

Contact Person: Greg Causey
Phone: 303-443-7500
Facsimile: 303-443-7501

Date Prepared: November 4, 2007

JAN 24 2008

Name of Device and Name/Address of Sponsor

Lanx Intervertebral Body Fusion Device

Lanx, LLC
390 Interlocken Crescent, Suite 890
Broomfield, CO 80021

Common or Usual Name

Intervertebral Body Fusion Device

Classification Name

Orthosis, spinal intervertebral fusion

Predicate Devices

Zimmer Spine, Inc. BAK™ Vista Interbody Fusion System
DePuy AcroMed, Inc. Lumbar I/F Cage® with VSP® Spine System
Lanx, LLC, Lanx Vertebral Body Replacement Device

Intended Use / Indications for Use

The Lanx Intervertebral Body Fusion Device ("Lanx Fusion System") is indicated for use with autogenous bone graft in skeletally mature patients with degenerative disc disease ("DDD") at one or two contiguous spinal levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should have had six months of non-operative treatment. These DDD patients may have had a previous non-fusion spinal surgery at the involved spinal level(s), and may have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). The Lanx Fusion System is to be implanted via an anterior or posterior approach and is to be combined with supplemental fixation. Approved supplemental fixation systems include the Lanx Spinal Fixation System.

Technological Characteristics

The Lanx Fusion System is made of PEEK-OPTIMA®. The Fusion System has a hollowed out area to accommodate autogenous bone graft, and transverse grooves to improve fixation and stability. It is available in a variety of different sizes accommodate anatomical variation in different vertebral levels and/or patient anatomy. The Lanx Fusion System is provided non-sterile.

Performance Data

Performance testing was conducted per ASTM F2077-03 and ASTM F2267-04. In all instances, the Lanx Fusion System met acceptance criteria and functioned as intended.

Substantial Equivalence

The Lanx Fusion System is as safe and effective as the previously cleared Lanx Vertebral Body Replacement Device and the previously approved, and now reclassified, Zimmer Spine, Inc. BAK™ Vista Interbody Fusion System and the DePuy AcroMed, Inc. Lumbar I/F Cage® with VSP® Spine System (the "Predicate Devices").

The Lanx Fusion System has the same intended use/indications, and similar technological characteristics and principles of operation as its predicate devices. The minor technological differences between the Lanx Fusion System and its predicate devices raise no new issues of safety or effectiveness. Performance data demonstrate that the Lanx Fusion System is as safe and effective as the predicate devices. Thus, the Lanx Fusion System is substantially equivalent.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JAN 24 2008

Lanx, LLC
% Mr. Greg Causey
390 Interlocken Crescent, Suite 890
Broomfield, CO 80021

Re: K073144
Trade/Device Name: Lanx Intervertebral Body Fusion Device
Regulation Number: 21 CFR 888.3080
Regulation Names: Intervertebral body fusion device
Regulatory Class: II
Product Code: MAX
Dated: November 6, 2007
Received: November 7, 2007

Dear Mr. Causey:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use Statement

510(k) Number (if known): K073144

Device Name: **Lanx Intervertebral Body Fusion Device**

Indications for Use:

The Lanx Intervertebral Body Fusion Device ("Lanx Fusion System") is indicated for use with autogenous bone graft in skeletally mature patients with degenerative disc disease ("DDD") at one or two contiguous spinal levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should have had six months of non-operative treatment. These DDD patients may have had a previous non-fusion spinal surgery at the involved spinal level(s), and may have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). The Lanx Fusion System is to be implanted via an anterior or posterior approach and is to be combined with supplemental fixation. Approved supplimental fixation systems include the Lanx Spinal Fixation System.

Prescription Use X AND/OR Over-The-Counter Use

(Part 21 C.F.R. 801 Subpart D) (21 C.F.R. 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of General, Restorative,
and Neurological Devices

510(k) Number K073144